Skip to main content

REGENXBIO Inc. (RGNX)

NASDAQ: RGNX · Delayed Price · USD
43.48 0.42 (0.98%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap1.83B
Revenue (ttm)161.28M
Net Income (ttm)-145.23M
Shares Out42.51M
EPS (ttm)-3.65
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume250,949
Open43.33
Previous Close43.06
Day's Range42.43 - 43.54
52-Week Range26.40 - 50.26
Beta1.20
AnalystsBuy
Price Target65.13 (+49.8%)
Est. Earnings DateNov 3, 2021

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It i...

IndustryBiotechnology
IPO DateSep 17, 2015
CEOKenneth Mills
Employees306
Stock ExchangeNASDAQ
Ticker SymbolRGNX
Full Company Profile

Financial Performance

In 2020, REGENXBIO Inc.'s revenue was $154.57 million, an increase of 338.70% compared to the previous year's $35.23 million. Losses were -$111.25 million, 17.4% more than in 2019.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for REGENXBIO Inc. stock is "Buy." The 12-month stock price forecast is 65.13, which is an increase of 49.79% from the latest price.

Price Target
$65.13
(49.79% upside)
Analyst Consensus: Buy

News

AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy

AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.

Other symbols:ABBV
1 week ago - Zacks Investment Research

REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie

REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.

Other symbols:ABBV
1 week ago - Zacks Investment Research

REGENXBIO (RGNX) Moves 31.2% Higher: Will This Strength Last?

REGENXBIO (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th...

1 week ago - Zacks Investment Research

Eyes Have It in AbbVie Deal With Regenxbio

To expand its footprint in eye care, AbbVie Inc.( ABBV , Financial) has struck a billion-dollar deal to gain access to a gene therapy used to treat several common kinds of eye disease. The Chicago-area ...

Other symbols:ABBV
1 week ago - GuruFocus

Why Regenxbio Stock Is Way Up Today

American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration.

1 week ago - The Motley Fool

Why Regenxbio Shares Are Trading Higher Today

Regenxbio Inc (NASDAQ: RGNX) is trading significantly higher Monday after the company, and AbbVie Inc (NYSE: ABBV), announced an eye care collaboration. The companies will develop and commercialize RGX-...

1 week ago - Benzinga

Here's why Regenxbio shares are up close to 30% on Monday morning

Regenxbio Inc (NASDAQ: RGNX) jumped about 30% in the stock market on Monday morning as it announced a partnership with the biopharmaceutical giant AbbVie Inc (NYSE: ABBV). “In collaboration with REGENXB...

1 week ago - Invezz

AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration

AbbVie Inc (NYSE: ABBV) and Regenxbio Inc (NASDAQ: RGNX) have partnered to develop and commercialize RGX-314, potential one-time gene therapy for wet age-related macular degeneration (wet AMD), diabetic...

Other symbols:ABBV
1 week ago - Benzinga

AbbVie and REGENXBIO Announce Eye Care Collaboration

NORTH CHICAGO, Ill. and ROCKVILLE, Md.

Other symbols:ABBV
1 week ago - PRNewsWire

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Sept. 7, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences, which will each be held in a virtual meeting format...

2 weeks ago - PRNewsWire

Dr. Jean Bennett and George Migausky Join REGENXBIO Board of Directors

ROCKVILLE, Md., Sept. 7, 2021 /PRNewswire/ --  Renowned gene therapy pioneer and biotechnology executive bring extensive R&D leadership and financial and operational expertise to the Board REGENXBIO Inc...

2 weeks ago - PRNewsWire

Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -25.93% and -20.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights

ROCKVILLE, Md., Aug. 9, 2021 /PRNewswire/ -- Enrollment in RGX-314 programs is on-track, including the pivotal program for the treatment of wet AMD utilizing subretinal delivery, and the Phase II trials...

1 month ago - PRNewsWire

REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2021 Financial Results and Recent Operational...

ROCKVILLE, Md., Aug. 2, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, August 9, 2021, at 4:30 p.m.

1 month ago - PRNewsWire

Earnings Preview: Regenxbio (RGNX) Q2 Earnings Expected to Decline

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Regenxbio's Hunter Syndrome Gene Therapy Shows Efficacy Signals, Cognitive Development Up To Two Years

Regenxbio Inc (NASDAQ: RGNX) has announced a safety update and additional positive interim data from its ongoing Phase 1/2 trial of RGX-121 to treat patients up to 5 years old diagnosed with Mucopolysac...

4 months ago - Benzinga

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hun...

ROCKVILLE, Md., May 14, 2021 /PRNewswire/ -- RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events Biomarkers and measures of neurodevel...

4 months ago - PRNewsWire

REGENXBIO to Present at Upcoming Investor Conferences

ROCKVILLE, Md., May 6, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the following May investor conferences, which will each be held in a virtual meeting format: ...

4 months ago - PRNewsWire

Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -6.19% and -32.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights

ROCKVILLE, Md., May 5, 2021 /PRNewswire/ -- Enrollment ongoing in ATMOSPHERE™, the first of two planned pivotal trials for the subretinal delivery of RGX-314 for the treatment of wet AMD Continued progr...

4 months ago - PRNewsWire

Preview: Regenxbio's Earnings

On Wednesday, May 05, Regenxbio (NASDAQ:RGNX) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

4 months ago - Benzinga

REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Hig...

ROCKVILLE, Md., April 28, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 5, 2021, at 4:30 p.m.

4 months ago - PRNewsWire

REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting

ROCKVILLE, Md., April 27, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that four oral and nine poster presentations will be presented at the American Society of Gene and Cell Thera...

4 months ago - PRNewsWire

REGENXBIO To Present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit

ROCKVILLE, Md., April 21, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran M.

5 months ago - PRNewsWire

REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (H...

ROCKVILLE, Md., April 14, 2021 /PRNewswire/ -- First patient dosed at third dose level in ongoing trial of RGX-121, a one-time gene therapy for MPS II; total of nine patients have been dosed at four lea...

5 months ago - PRNewsWire